A Study of the Capsule and Tablet Forms of Tafamidis and the Effect of Food on Tafamidis Tablet in Healthy Adults
A Phase 1, Open-Label, Randomized, Crossover, Single Dose Study to Determine the Bioequivalence of 12.2 mg Tafamidis Free Acid Tablets and Commercial 20 mg Tafamidis Meglumine Capsules Administered Under Fasted Conditions and the Effect of Food on Oral Bioavailability of 12.2 mg Tafamidis Free Acid Tablets in Healthy Adult Participants
Category & Conditions: Cardiovasular Diseases and Conditions
Medicine: VYNDAQEL® (TAFAMIDIS MEGLUMINE)
ClinicalTrials.gov Identifier (NCT): NCT05498701
Protocol ID: B3461103
PrintDownloadOpen Plain Language Summary Result: Click here